パロスラン

Palosuran

HCID 10173280

基本情報

CAS
540769-28-6
標準SMILES
Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1
InChIKey
WYJCYXOCHXWTHG-UHFFFAOYSA-N
分子式
C25H30N4O2
平均分子量
418.5 g/mol
単同位体質量
418.23687621

名称と識別子

優先名称
Palosuran
IUPAC
1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea
現地名
パロスラン
英語名
Urea, N-[2-[4-hydroxy-4-(phenylMethyl)-1-piperidinyl]ethyl]-N'-(2-Methyl-4-quinolinyl)-
分子式
C25H30N4O2
分子量
418.53

名称と別名

Palosuran540769-28-6ACT-0583621-(2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)ureaULD9ZKE4571-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)ureaDTXSID002024061-[2-[4-hydroxy-4-(phenylmethyl)piperidin-1-yl]ethyl]-3-(2-methylquinolin-4-yl)ureapalosuranum1-(2-(4-hydroxy-4-(phenylmethyl)piperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)ureaRefChem:169773DTXCID60124897
名称をさらに表示
パロスラン1-[2-(4-ベンジル-4-ヒドロキシピペリジン-1-イル)エチル]-3-(2-メチルキノリン-4-イル)尿素1-[2-(4-ヒドロキシ-4-ベンジルピペリジノ)エチル]-3-(2-メチルキノリン-4-イル)尿素ACT 058362PALOSURAN,, >98%Palosuran (ACT058362)ACT 058362PALOSURAN,Palosuran, 10 mM in DMSOACT 058362PALOSURAN,, >98%N-[2-[4-Hydroxy-4-(phenylmethyl)-1-piperidinyl]ethyl]-N'-(2-methyl-4-quinolinyl)urea
ACT0583621-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea sulfate saltPalosuran [INN]ACT058362 (Palosuran)CHEMBL567303GTPL3516MFCD07772352Urea, N-[2-[4-hydroxy-4-(phenylMethyl)-1-piperidinyl]ethyl]-N'-(2-Methyl-4-quinolinyl)-

データベース識別子

CAS
540769-28-6
PubChem CID
10173280
DTXSID
DTXSID00202406
ChEMBL
CHEMBL567303
UNII
ULD9ZKE457
Nikkaji
J2.917.197A

物性

構造計算による物性

XLogP
3.3
極性表面積
77.5 Ų
水素結合供与体数
3
水素結合受容体数
4
回転可能結合数
6
重原子数
31

物理化学的性質

沸点
612.9 · 612.9±55.0 °C(Predicted)
比重(密度)
1.235 · 1.235±0.06 g/cm3(Predicted)
貯蔵温度
-20 °C · Store at -20°C
溶解性
10 mg/ml; · DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml; Ethanol: 0.5 mg/ml
外見
A crystalline solid
酸解離定数(Pka)
12.95 · 12.95±0.43(Predicted)

安全と法規制

安全データ

wgk
WGK 3
ストレージクラス
11 - Combustible Solids

化学と産業

応用分野 · 1 件

説明Palosuran is an antagonist of the urotensin II receptor (UTR; IC50s = 3.6 and 1,475 nM for CHO cell membranes expressing human and rat recombinant receptors, respectively). It inhibits contraction of isolated rat aortic rings induced by urotensin II (Item Nos. 24711 | 24753) in a concentration-dependent manner. Palosuran (300 mg/kg twice per day) reduces plasma endothelin-1 , urotensin II, and TGF-β1 levels, as well as the main pulmonary arterial pressure and right ventricular hypertrophy index in a rat model of pulmonary arterial hypertension (PAH) induced by monocrotaline . Palosuran (300 mg/kg per day) reduces serum glucose, cholesterol, and triglyceride levels and increases survival in a rat model of diabetes induced by streptozotocin (STZ; ). It also decreases albuminuria and global kidney lesion scores in STZ-induced diabetic rats.

サプライヤー55 社

Career Henan Chemica Co+86-0371-86658258 +86-13203830695 · [email protected]
武汉英诺医药科技有限公司+86-027-59232304 15387063101 · [email protected]
成都超九八生物科技有限公司13348960310 13348960310 · [email protected]
江苏艾康生物医药研发有限公司025-58851090 19370895928 · [email protected]
上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]

関連反応

7 件

化合物ノート

読み込み中…